May 8th, 2022
Podcast 290: USPSTF’s new take on aspirin and primary prevention of CVD
The U.S. Preventive Services Task Force recently issued its sixth set of guidelines on using daily aspirin to prevent cardiovascular disease. The guidelines appeared in JAMA — whose editors asked our guest, Dr. Allan Brett, to write an editorial evaluation. This edition carries Brett’s advice on using the new guidelines in daily clinical practice. Brett’s JAMA editorial USPSTF […]
March 9th, 2018
Podcast 217: Aspirin and rivaroxaban “comparably effective and safe” for prophylaxis after arthroplasty
The EPCAT II trial examined whether aspirin and rivaroxaban were clinically equivalent in the extended prophylaxis of venous thromboembolism after hip or knee replacement. They proved “comparably effective and safe,” according to our guest, Dr. David Anderson, the study’s first author. An editorial in the New England Journal of Medicine, where the study appeared in […]
May 2nd, 2012
Podcast 154: Treating heart failure’s hypercoagulable state — warfarin or aspirin?
Heart failure brings problems associated with hypercoagulation, such as stroke and sudden death. An international study followed some 2300 patients with heart failure (ejection fractions of 35% or less) and in stable sinus rhythm for a mean of 3.5 years, randomizing them to treatment with either warfarin or aspirin. The two treatment groups showed about the same […]
November 4th, 2011
Podcast 136: Aspirin lowers colorectal risks in Lynch syndrome — what are the implications for everyone else?
Last week’s Lancet article on the effect of aspirin on risks for colorectal cancer in patients with Lynch syndrome — a group at particularly high risk — may hold implications for preventing sporadic colon cancers. Our interview with Prof. Sir John Burn, the study’s first author, explores those implications as well speculations on why we human […]
About the Podcast
Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.
Follow us:
